Watch Demo

Clinical Trials Market Research Report by Design, Phase, Indication, Country - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - North America Forecast 2023-2030

Clinical Trials Market Research Report by Design, Phase, Indication, Country - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - North America Forecast 2023-2030
  • Publish Date:January 2023

  • Number of Pages:129

  • Report ID:6390731

  • Format:PDF

  • Publisher:360iResearch

$ 3949

Summary

Clinical Trials Market Research Report by Design (Interventional Study and Observational Study), Phase, Indication, Country - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - North America Forecast 2023-2030

The North America Clinical Trials Market size was estimated at USD 8,931.56 million in 2022 and expected to reach USD 9,712.48 million in 2023, projecting growth at a CAGR of 9.08% to reach USD 17,903.99 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the North America Clinical Trials Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the North America Clinical Trials Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The North America Clinical Trials Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the North America Clinical Trials Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the North America Clinical Trials Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Design, the market is studied across Interventional Study and Observational Study. The Interventional Study is further studied across Adaptive Clinical Trial, Non-randomized Control Trial, and Randomized Control Trial. The Observational Study is further studied across Case Control Study, Cohort Study, Cross Sectional Study, and Ecological Study.

Based on Phase, the market is studied across Phase I, Phase II, Phase III, and Phase IV.

Based on Indication, the market is studied across Autoimmune/Inflammation, Cardiovascular, CNS condition, Diabetes, Infectious Diseases, Obesity, Oncology, and Pain management.

Based on Country, the market is studied across Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the North America Clinical Trials Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The North America Clinical Trials Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The North America Clinical Trials Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The North America Clinical Trials Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the North America Clinical Trials Market, including Accell Clinical Research, LLC, Atlant Clinical Ltd., Charles River Laboratories International, Inc., Clinipace, Eli Lilly and Company, Icon PLC, IQVIA Holdings, Inc., Novo Nordisk A/S, Parexel International Corporation, Pfizer Inc., ProPharma Group Holdings, LLC, SGS S.A., SIRO Clinpharm Private Limited, Syneos Health, Inc., Thermo Fisher Scientific Inc., and Wuxi AppTec Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the North America Clinical Trials Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the North America Clinical Trials Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the North America Clinical Trials Market?
4. What is the competitive strategic window for opportunities in the North America Clinical Trials Market?
5. What are the technology trends and regulatory frameworks in the North America Clinical Trials Market?
6. What is the market share of the leading vendors in the North America Clinical Trials Market?
7. What modes and strategic moves are considered suitable for entering the North America Clinical Trials Market?

Table of contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Clinical Trials Market, by Design
6.1. Introduction
6.2. Interventional Study
6.3.1. Adaptive Clinical Trial
6.3.2. Non-randomized Control Trial
6.3.3. Randomized Control Trial
6.3. Observational Study
6.4.1. Case Control Study
6.4.2. Cohort Study
6.4.3. Cross Sectional Study
6.4.4. Ecological Study

7. Clinical Trials Market, by Phase
7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
7.5. Phase IV

8. Clinical Trials Market, by Indication
8.1. Introduction
8.2. Autoimmune/Inflammation
8.3. Cardiovascular
8.4. CNS condition
8.5. Diabetes
8.6. Infectious Diseases
8.7. Obesity
8.8. Oncology
8.9. Pain management

9. Canada Clinical Trials Market
9.1. Introduction

10. Mexico Clinical Trials Market
10.1. Introduction

11. United States Clinical Trials Market
11.1. Introduction

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Product Portfolio Analysis, By Key Player
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Accell Clinical Research, LLC
13.2. Atlant Clinical Ltd.
13.3. Charles River Laboratories International, Inc.
13.4. Clinipace
13.5. Eli Lilly and Company
13.6. Icon PLC
13.7. IQVIA Holdings, Inc.
13.8. Novo Nordisk A/S
13.9. Parexel International Corporation
13.10. Pfizer Inc.
13.11. ProPharma Group Holdings, LLC
13.12. SGS S.A.
13.13. SIRO Clinpharm Private Limited
13.14. Syneos Health, Inc.
13.15. Thermo Fisher Scientific Inc.
13.16. Wuxi AppTec Inc.

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. NORTH AMERICA CLINICAL TRIALS MARKET: RESEARCH PROCESS
FIGURE 2. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, 2022 VS 2030
FIGURE 3. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 5. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. NORTH AMERICA CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 7. NORTH AMERICA CLINICAL TRIALS MARKET DYNAMICS
FIGURE 8. NORTH AMERICA CLINICAL TRIALS MARKET PORTER'S FIVE FORCES ANALYSIS
FIGURE 9. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2022 VS 2030 (%)
FIGURE 10. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. NORTH AMERICA CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY DESIGN, 2030
FIGURE 12. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
FIGURE 13. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY ADAPTIVE CLINICAL TRIAL, 2018-2030 (USD MILLION)
FIGURE 14. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY NON-RANDOMIZED CONTROL TRIAL, 2018-2030 (USD MILLION)
FIGURE 15. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY RANDOMIZED CONTROL TRIAL, 2018-2030 (USD MILLION)
FIGURE 16. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
FIGURE 17. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY CASE CONTROL STUDY, 2018-2030 (USD MILLION)
FIGURE 18. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY COHORT STUDY, 2018-2030 (USD MILLION)
FIGURE 19. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY CROSS SECTIONAL STUDY, 2018-2030 (USD MILLION)
FIGURE 20. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY ECOLOGICAL STUDY, 2018-2030 (USD MILLION)
FIGURE 21. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022 VS 2030 (%)
FIGURE 22. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. NORTH AMERICA CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY PHASE, 2030
FIGURE 24. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE I, 2018-2030 (USD MILLION)
FIGURE 25. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2030 (USD MILLION)
FIGURE 26. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE III, 2018-2030 (USD MILLION)
FIGURE 27. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE IV, 2018-2030 (USD MILLION)
FIGURE 28. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 29. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 30. NORTH AMERICA CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2030
FIGURE 31. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION, 2018-2030 (USD MILLION)
FIGURE 32. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
FIGURE 33. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY CNS CONDITION, 2018-2030 (USD MILLION)
FIGURE 34. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
FIGURE 35. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
FIGURE 36. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY OBESITY, 2018-2030 (USD MILLION)
FIGURE 37. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
FIGURE 38. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
FIGURE 39. CANADA CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 40. MEXICO CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 41. UNITED STATES CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 42. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 43. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 44. UNITED STATES CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 45. NORTH AMERICA CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 46. NORTH AMERICA CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 47. NORTH AMERICA CLINICAL TRIALS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

List of Tables

TABLE 1. NORTH AMERICA CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 5. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 6. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
TABLE 7. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 8. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY ADAPTIVE CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 9. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY ADAPTIVE CLINICAL TRIAL, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 10. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY NON-RANDOMIZED CONTROL TRIAL, 2018-2030 (USD MILLION)
TABLE 11. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY NON-RANDOMIZED CONTROL TRIAL, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 12. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY RANDOMIZED CONTROL TRIAL, 2018-2030 (USD MILLION)
TABLE 13. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY RANDOMIZED CONTROL TRIAL, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 14. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
TABLE 15. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 16. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY CASE CONTROL STUDY, 2018-2030 (USD MILLION)
TABLE 17. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY CASE CONTROL STUDY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 18. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY COHORT STUDY, 2018-2030 (USD MILLION)
TABLE 19. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY COHORT STUDY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 20. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY CROSS SECTIONAL STUDY, 2018-2030 (USD MILLION)
TABLE 21. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY CROSS SECTIONAL STUDY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY ECOLOGICAL STUDY, 2018-2030 (USD MILLION)
TABLE 23. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY ECOLOGICAL STUDY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 25. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE I, 2018-2030 (USD MILLION)
TABLE 26. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 27. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2030 (USD MILLION)
TABLE 28. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE III, 2018-2030 (USD MILLION)
TABLE 30. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE IV, 2018-2030 (USD MILLION)
TABLE 32. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION, 2018-2030 (USD MILLION)
TABLE 35. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 37. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY CNS CONDITION, 2018-2030 (USD MILLION)
TABLE 39. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY CNS CONDITION, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 41. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 43. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY OBESITY, 2018-2030 (USD MILLION)
TABLE 45. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 47. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 49. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. CANADA CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 51. CANADA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 52. CANADA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 53. CANADA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. MEXICO CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 55. MEXICO CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 56. MEXICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 57. MEXICO CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. NORTH AMERICA CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 64. NORTH AMERICA CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 65. NORTH AMERICA CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 66. NORTH AMERICA CLINICAL TRIALS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 67. NORTH AMERICA CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 68. NORTH AMERICA CLINICAL TRIALS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 69. NORTH AMERICA CLINICAL TRIALS MARKET MERGER & ACQUISITION
TABLE 70. NORTH AMERICA CLINICAL TRIALS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 71. NORTH AMERICA CLINICAL TRIALS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 72. NORTH AMERICA CLINICAL TRIALS MARKET INVESTMENT & FUNDING
TABLE 73. NORTH AMERICA CLINICAL TRIALS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 74. NORTH AMERICA CLINICAL TRIALS MARKET: LICENSE & PRICING

Companies Mentioned

Accell Clinical Research, LLC
Atlant Clinical Ltd.
Charles River Laboratories International, Inc.
Clinipace
Eli Lilly and Company
Icon PLC
IQVIA Holdings, Inc.
Novo Nordisk A/S
Parexel International Corporation
Pfizer Inc.
ProPharma Group Holdings, LLC
SGS S.A.
SIRO Clinpharm Private Limited
Syneos Health, Inc.
Thermo Fisher Scientific Inc.
Wuxi AppTec Inc.

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.